Bloodstream Infection Testing Market Outlook:
Bloodstream Infection Testing Market size was over USD 6.08 billion in 2025 and is poised to exceed USD 10.99 billion by 2035, witnessing over 6.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of bloodstream infection testing is estimated at USD 6.41 billion.
The growing frequency of infectious diseases is the key factor driving the market growth of bloodstream infection testing. The increasing population and limited constancy to hygiene practices increase the possibility of infectious diseases. According to the World Health Organization, in 2020, there were around 48.9 million cases and 11 million deaths caused due to sepsis worldwide, representing 20% of all global deaths.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of bloodstream infection testing is estimated at USD 6.41 billion.
The global bloodstream infection testing market size was more than USD 6.08 billion in 2025 and is anticipated to witness a CAGR of over 6.1%, crossing USD 10.99 billion revenue by 2035.
North America bloodstream infection testing market will secure over 34% share by 2035, driven by the rapid growth in the geriatric population and the presence of major key players investing in bloodstream infection testing devices.
Key players in the market include Abbott Laboratories, biomerieux SA, Bruker Corporation, Danaher Corporation, DiaSorin S.p.A, Siemens Healthineers AG, Thermo Fisher Scientific Inc., T2 Biosystems, Inc., Accelerate Diagnostics, Inc., F. Hoffmann-La Roche Ltd.
